GSK recently announced that the US Food and Drug Administration (FDA)ManagementBureau (FDA) has approved its combination vaccine Penmenvy (MenABCWY) for use in individuals aged 10 to 25. The vaccine is designed to prevent invasive meningococcal disease (IMD) caused by five major serogroups (A, B, C, W, and Y) of Neisseria meningitidis. IMD is a rare but severe disease that can lead to meningitis and sepsis, potentially resulting in life-threatening complications or even death. Even with treatment, approximately one in six patients with IMD may die within 24 hours of symptom onset. Additionally, about one in five survivors may suffer from long-term sequelae such as brain damage, amputation, hearing loss, and neurological issues. These five serogroups account for nearly all IMD cases in most regions globally.
Penmenvy combines two meningococcal vaccines approved by GSK——The antigen components of Bexsero (for group B) and Menveo (for groups A, C, Y, and W) form a "five-in-one" vaccine.This combination aims to reduce the number of injections and simplifyImmunityVaccination procedures, thereby increasing vaccine coverage and helping to reduce the overall burden of disease.
This FDA approval is based on the results of two pivotal Phase III clinical trials, which evaluated the safety, tolerability, and immune response of Penmenvy in more than 4,800 participants aged 10 to 25. The trial results showed,Penmenvy is non-inferior to a single dose of Menveo vaccine in terms of immunogenicity and non-inferior to two doses of Bexsero vaccine in immune response against 110 different invasive strains of serogroup B meningococcal bacteria.Moreover, Penmenvy demonstrated good tolerability, with its safety profile consistent with Bexsero and Menveo.
GSK Chief Scientific Officer Tony Wood said, "We are pleased to leverage Penmenvy to improve meningococcal vaccination coverage in the United States, particularly for IMD caused by serogroup B. By combining two vaccines into one, we aim to simplify the vaccination process and protect more adolescents and young adults who are at high risk."
Notably, the number of meningococcal disease cases in the United States has sharply increased since 2021, surpassing pre-pandemic levels. The introduction of Penmenvy is expected to provide broader protection at this critical juncture, reducing the incidence of IMD and related complications.
The Advisory Committee on Immunization Practices (ACIP) of the U.S. Centers for Disease Control and Prevention (CDC) is scheduled to meet on February 26, 2025, to discuss recommendations for the use of Penmenvy in adolescents and young adults. This will provide further guidance for the widespread application of the vaccine and support public health prevention and control efforts.
The approval of Penmenvy, by integrating the advantages of existing vaccines, marks a significant advancement in the prevention of meningococcal disease, offering high-risk populations more comprehensive and convenient protection.
It is reported that this vaccine is expected to become a new blockbuster product.
